Headache News and Research

Latest Headache News and Research

LEO Pharma receives FDA approval for Picato topical gel to treat AK

LEO Pharma announced today that the U.S. Food and Drug Administration (FDA) approved Picato (ingenol mebutate) gel (0.015%, 0.05%) for the topical treatment of actinic keratosis.

27 Jan 2012

FDA approves UCB's Keppra for treatment of partial onset seizures in infants

UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Keppra (levetiracetam) tablets and oral solution as adjunctive therapy in the treatment of partial onset seizures in adults and children one month of age and older with epilepsy.

27 Jan 2012

IHS experts develop new guidelines for migraine clinical trials

Experts from the International Headache Society (IHS) have developed new recommendations for conduct of acute and preventive migraine clinical trials. The third edition of Migraine Clinical Trials Guidelines is now available in the IHS journal Cephalalgia, which is published by SAGE.

25 Jan 2012

A delay in signing up for Medicare can lead to big penalties

Reuters reports on how seniors who wait too long to sign up for Medicare Part B could face costly penalties. Meanwhile, CQ HealthBeat reports on the political implications of Medicare's monthly premiums.

24 Jan 2012

Baxter to commence second GAMMAGARD LIQUID Phase III trial in Alzheimer's

Baxter International Inc. today provided an update on its clinical program evaluating the use of its GAMMAGARD LIQUID 10%, for the treatment of mild to moderate Alzheimer's disease.

From Baxter International Inc. 24 Jan 2012

Takeda receives FDA approval for VELCADE sNDA to treat MM

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE(bortezomib), which updates the label to include the subcutaneous method of administration in all approved indications: multiple myeloma and mantle cell lymphoma after at least one prior therapy.

24 Jan 2012

EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC

MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.

21 Jan 2012

Study demonstrates possibility of curing hepatitis C without use of interferon

Bristol-Myers Squibb Company today announced the full results, published in the New England Journal of Medicine, from a Phase II clinical trial in patients with hepatitis C virus (HCV) genotype 1 who had not responded to prior therapy with PEG-interferon alfa and ribavirin ('null responders').

19 Jan 2012

ConsultantLive launches topic center on migraines

UBM Medica's announced today that ConsultantLive now features special coverage focused on helping clinicians diagnose and control migraine headaches.

19 Jan 2012

Integrative medicine now available for pediatric patients at JMBCIM

Integrative medicine, the field of medicine which combines the use of conventional and complementary techniques in reaching health and wellness goals, is now available for pediatric patients through the Integrative Pediatrics program at the Jefferson-Myrna Brind Center of Integrative Medicine.

19 Jan 2012

Gilead Sciences receives FDA approval for Viread to treat pediatric HIV infection

Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients ages 2-12.

19 Jan 2012

Voraxaze receives FDA approval for treatment of toxic methotrexate levels

The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.

18 Jan 2012

ForSight VISION4 to receive first milestone payment for Lucentis drug delivery device

Genentech, a member of the Roche Group, today announced it will make its first milestone payment to ForSight VISION4, Inc. as part of an exclusive license agreement to develop the company's investigational drug delivery device, designed to provide sustained delivery of Lucentis (ranibizumab).

13 Jan 2012

ViroPharma's NDS for Cinryze receives Health Canada's Priority Review status

ViroPharma Incorporated today announced that Health Canada has granted the company Priority Review status for its New Drug Submission (NDS) for Cinryze (C1 inhibitor [human]).

13 Jan 2012

Shire, Janssen enter development and marketing agreement for Resolor

Shire plc, the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V.

11 Jan 2012

Shire acquires rights to develop and market Resolor in the U.S.

10 Jan 2012

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter International Inc. today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% for the treatment of multifocal motor neuropathy.

From Baxter International Inc. 9 Jan 2012